The drug is a new research molecule from the company's neurosciences portfolio. Pfizer holds an international patent for this molecule. However, it has not been granted patent for the product in India.
The pharma major has launched the drug in 150 mg and 75 mg capsules at Rs 1,108 a strip of 14 and Rs 739 a strip of 14, respectively.
Kewal Handa, managing director, Pfizer India, said Lyrica represents a major achievement in Pfizer's research programme and confirms its leadership in bringing life-changing medicines to patients.
Pfizer claims that the drug was tested in over 10,000 patients in one of the most extensive clinical research programmes ever.
Sources in the company said Lyrica is the first pregabalin molecule to be approved by Indian regulatory authorities, based on results from clinical trials conducted abroad as well as in Indian patients.
The new drug relieves neuropathic pain and manages co-morbid conditions like sleep disturbance, anxiety and depression, thus improving the overall quality of life. It is estimated that neuropathic pain affects over 2 million people in India.
Neuropathic pain is a chronic pain condition that sets in consequent upon damage to the nervous system resulting from a variety of conditions including diabetes, herpes zoster, HIV, cancer, stroke, spinal cord injury, among others.
The syndrome causes disability and makes life distressful on the back of its adverse affect on physical/functional and psychological health.
© 2025